XML 64 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 158,447,065 $ 22,196,097
Short-term investments 111,550,890 67,338,017
Accounts receivable 641,643 700,073
Accounts receivable from affiliated entities 634,198 1,332,044
Prepaid expenses and other current assets 2,479,204 1,584,598
Prepaid expenses and other current assets from affiliated entities 1,790,609 1,050,140
Total current assets 275,543,609 94,200,969
Fixed assets, net 12,104,410 12,773,017
Investment in affiliated entities 21,210,745 6,315,356
Intangible assets, net 3,557,081 3,693,851
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 13,511,381 13,783,009
Other assets 2,480,087 2,672,024
Total assets 338,920,684 143,951,597
Current liabilities:    
Accounts payable and accrued expenses 11,019,582 18,237,258
Accounts payable and accrued expenses due to affiliated entities 263,456 729,729
Accrued clinical trial expenses 5,061,166 4,049,727
Deferred revenue 67,269 92,353
Deferred revenue from affiliated entities 525 31,775
Operating lease liability 2,132,045 2,074,842
Grant funding liability 13,091,424 6,065,212
Grant funding liability from affiliated entities 659,175 708,425
Total current liabilities 32,294,642 31,989,321
Deferred revenue, net of current portion 100,354 101,567
Derivative liability 22,041,000 8,819,023
Operating lease liability, net of current portion 19,834,770 20,409,922
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 135,000 135,000
Other liabilities 73,444 36,943
Total liabilities 151,066,581 138,546,739
Stockholders’ equity:    
Preferred stock 0 0
Common stock 145,915 101,361
Additional paid-in capital 957,962,628 742,646,785
Accumulated deficit (772,326,709) (739,785,655)
Accumulated other comprehensive income (loss) (1,456,930) 472,608
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 184,324,904 3,435,099
Non-controlling interest 3,529,199 1,969,759
Total stockholders’ equity 187,854,103 5,404,858
Total liabilities and stockholders’ equity 338,920,684 143,951,597
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 63,730,182 64,180,325
Convertible Bonds [Member]    
Current liabilities:    
Convertible debt $ 12,825,143 $ 12,842,592